Treatment with NSC69792 leads to the accumulation of DNA damage and reduced NF-κB signaling in cancer cells, ultimately causing cell death in lymphoma and multiple myeloma (MM) cell lines [204]. The gene discussed is NFKB1; the disease is Miyoshi myopathy.